Although previous studies have attempted to isolate the effect of pharmaceutical spending on health outcomes, most have been limited by analysis of inherently heterogeneous inter-country data. This study focuses on one particular health outcome — infant mortality at the state level in the U.S. — and shows that its important determinants include: (1) pharmaceutical expenditures; (2) health economic infrastructure (e.g. number of practicing physicians, number of hospital beds); (3) socio-demographics (e.g. teenage birth rate, low-weight births, high school graduation rate, racial composition of state population); and (4) state-level economic aggregates (e.g. a disposable income, percent of population below the poverty line).
Cremieux, P.-Y., Ouellette, P., Meilleur, M.-C., Leong, S., Greenberg, P. and Birnbaum, H. (2001), "Pharmaceutical spending and health outcomes in the united states", Farquhar, I., Summers, K. and Sorkin, A. (Ed.) Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development, Vol. 14), Emerald Group Publishing Limited, Bingley, pp. 59-75. https://doi.org/10.1016/S0194-3960(01)14004-7
Emerald Group Publishing Limited
Copyright © 2001, Emerald Group Publishing Limited